利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.019 秒)

    Process of isolating extract from the Euphorbia obesa plant and methods for using the same
    1.
    发明授权
    Process of isolating extract from the Euphorbia obesa plant and methods for using the same 失效
    从大戟属植物中分离提取物的方法及其使用方法

    公开(公告)号：US06923993B2

    公开(公告)日：2005-08-02

    申请号：US10020816

    申请日：2001-12-12

    申请人： Nicholas D. Donato ,  Nicholas J. Donato ,  David C. Sample ,  Margot Perez ,  John S. McMurray ,  Robert A Newman

    发明人： Nicholas D. Donato ,  Nicholas J. Donato ,  David C. Sample ,  Margot Perez ,  John S. McMurray ,  Robert A Newman

    IPC分类号： A61K36/47 ,  A61P35/00 ,  A61P43/00 ,  C12N20060101 ,  C12N5/22 ,  A61K35/78

    CPC分类号： A61K36/47

    摘要： The present invention is directed to a process of isolating an extract from a Euphorbia obesa (EO) plant by: preparing a sample of said plant comprising removal of the latex material; dissolving said sample with first solvent to form a solution; separating said solution into a liquid and a pulp fraction; and purifying said pulp fraction. The isolated EO extract induces apoptosis and inhibits growth of a cancerous cell. Thus, the present invention is also directed to a method for inducing apoptosis and growth inhibition of a cancerous cell by contacting the cell with an effective amount of the EO extract by the process of the invention. Preferably, the extract is administered both to the tumor directly and intravenously. The preferred lines of cancerous cells are melanoma, non-small cell lung cancer, prostate cancer, breast carcinoma, ovarian cancer, lymphoma and leukemia cells.

    摘要翻译： 本发明涉及通过以下步骤从大戟属植物（Euphorbia obesa，EO）植物中分离提取物的方法：制备所述植物的样品，包括除去胶乳材料; 用第一溶剂溶解所述样品以形成溶液; 将所述溶液分离成液体和纸浆馏分; 并纯化所述纸浆级分。 分离的EO提取物诱导凋亡并抑制癌细胞的生长。 因此，本发明还涉及通过本发明的方法使细胞与有效量的EO提取物接触来诱导癌细胞的凋亡和生长抑制的方法。 优选地，将提取物直接和静脉内施用于肿瘤。 癌细胞的优选系是黑素瘤，非小细胞肺癌，前列腺癌，乳腺癌，卵巢癌，淋巴瘤和白血病细胞。

    Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
    6.
    发明授权
    Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia 失效
    单独或与STI571组合使用c-Src抑制剂治疗白血病

    公开(公告)号：US08268837B2

    公开(公告)日：2012-09-18

    申请号：US11285664

    申请日：2005-11-22

    申请人： Nicholas J Donato ,  Doriano Fabbro ,  Paul W Manley ,  Jurgen Mestan ,  Markus Warmuth ,  Michael Hallek ,  Moshe Talpaz ,  Ji Wu

    发明人： Nicholas J Donato ,  Doriano Fabbro ,  Paul W Manley ,  Jurgen Mestan ,  Markus Warmuth ,  Michael Hallek ,  Moshe Talpaz ,  Ji Wu

    IPC分类号： A61K31/519

    CPC分类号： A61K35/02 ,  A61K31/506 ,  A61K31/519

    摘要： The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.

    摘要翻译： 本发明涉及一种组合，其包含（a）至少一种降低c-Src活性的化合物和（b）N- {5- [4-（4-甲基 - 哌嗪基 - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺或其单甲磺酸盐; 包含所述组合的药物组合物; 以及治疗具有白血病，特别是慢性骨髓性白血病的温血动物的方法，包括向所述动物施用至少一种抑制Src激酶家族成员，Btk激酶家族，Tec激酶家族的活性的化合物或 Raf激酶抑制剂，特别是抑制c-Src蛋白酪氨酸激酶活性或同时抑制c-Src蛋白酪氨酸激酶活性和Bcr-Abl酪氨酸激酶活性，单独或与Bcr-Abl抑制剂组合，特别是N - {5- [4-（4-甲基 - 哌嗪子基 - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺。

    Anti-IgM monoclonal antibodies and methods of their use
    8.
    发明授权
    Anti-IgM monoclonal antibodies and methods of their use 失效
    抗IgM单克隆抗体及其使用方法

    公开(公告)号：US06306626B1

    公开(公告)日：2001-10-23

    申请号：US08192507

    申请日：1994-02-07

    申请人： Michael G. Rosenblum ,  Nicholas J. Donato

    发明人： Michael G. Rosenblum ,  Nicholas J. Donato

    IPC分类号： A61K39395

    CPC分类号： C07K16/4283 ,  A61K38/00 ,  A61K47/6873

    摘要： The present invention provides an anti-IgM antibody conjugate comprising: a monoclonal antibody which binds selectively to IgM antibody, does not bind to IgG1 or IgG2 antibody, and has a G isotype; and a cytotoxic moiety conjugated to said monoclonal antibody. The present invention also provides a method for collecting hybridoma producing IgG isotype monoclonal antibodies comprising: treating a hybrid cell population with a monoclonal antibody which has a G isotype and binds selectively to IgM antibody but does not bind to IgG1 or IgG2 antibody; subjecting said resulting immuncomplexed cells to sorting; and collecting the cells which have not complexed with said antibodies.

    摘要翻译： 本发明提供了抗IgM抗体缀合物，其包含：与IgM抗体选择性结合的单克隆抗体，不结合IgG1或IgG2抗体，并且具有G同种型; 和与所述单克隆抗体缀合的细胞毒性部分。 本发明还提供了收集产生IgG同种型单克隆抗体的杂交瘤的方法，其包括：用具有G同种型的单克隆抗体治疗杂交细胞群，并选择性地结合IgM抗体但不结合IgG1或IgG2抗体; 对所得到的免疫复合细胞进行分选; 并收集与所述抗体未复合的细胞。

    Avidin-biotin immunoconjugates
    9.
    发明授权
    Avidin-biotin immunoconjugates 失效
    抗生物素蛋白 - 生物素免疫缀合物

    公开(公告)号：US06214974B1

    公开(公告)日：2001-04-10

    申请号：US08410390

    申请日：1995-03-27

    申请人： Michael G. Rosenblum ,  Nicholas J. Donato

    发明人： Michael G. Rosenblum ,  Nicholas J. Donato

    IPC分类号： A61K39395

    CPC分类号： B82Y5/00 ,  A61K38/00 ,  A61K47/6898 ,  A61K48/00 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/77 ,  C12N15/87

    摘要： The present invention provides a non-viral vector, comprising a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. Also, provided is a method of introducing genetic material inside a specific cell comprising the administration of the non-viral vector to a human, wherein said non-viral vector comprises a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. In addition, there is provided a method of delivering a cytotoxic moiety to a cell comprising the administration of the non-viral vector to a human.

    摘要翻译： 本发明提供非病毒载体，其包含具有与生物素化部分缀合的生物素结合元件的细胞结合成分。 此外，提供了将包含非病毒载体的给予的特定细胞内的遗传物质引入人的方法，其中所述非病毒载体包含具有与生物素化部分缀合的生物素结合元件的细胞结合成分。 此外，提供了向细胞递送细胞毒性部分的方法，所述方法包括向人施用非病毒载体。